Free Trial

FORA Capital LLC Acquires Shares of 15,103 Enovis Co. (NYSE:ENOV)

Enovis logo with Medical background

FORA Capital LLC bought a new stake in Enovis Co. (NYSE:ENOV - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 15,103 shares of the company's stock, valued at approximately $650,000.

Several other large investors also recently modified their holdings of the business. Benjamin F. Edwards & Company Inc. boosted its stake in Enovis by 28.1% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,691 shares of the company's stock worth $76,000 after purchasing an additional 371 shares during the period. Aigen Investment Management LP lifted its holdings in shares of Enovis by 5.1% in the third quarter. Aigen Investment Management LP now owns 8,859 shares of the company's stock valued at $381,000 after purchasing an additional 430 shares in the last quarter. FMR LLC boosted its position in shares of Enovis by 20.5% during the third quarter. FMR LLC now owns 2,840 shares of the company's stock worth $122,000 after buying an additional 484 shares during the period. Ridgewood Investments LLC acquired a new stake in Enovis in the 2nd quarter valued at approximately $44,000. Finally, State of Alaska Department of Revenue boosted its position in Enovis by 20.8% during the 3rd quarter. State of Alaska Department of Revenue now owns 6,482 shares of the company's stock worth $279,000 after acquiring an additional 1,115 shares during the last quarter. 98.45% of the stock is currently owned by institutional investors.

Enovis Stock Performance

NYSE ENOV traded up $0.36 during trading on Friday, reaching $48.81. 249,656 shares of the company's stock were exchanged, compared to its average volume of 581,045. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12. The business has a 50 day moving average price of $43.08 and a 200-day moving average price of $44.93. Enovis Co. has a fifty-two week low of $38.27 and a fifty-two week high of $65.03.

Enovis (NYSE:ENOV - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported $0.73 earnings per share for the quarter, topping analysts' consensus estimates of $0.62 by $0.11. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The business had revenue of $505.22 million for the quarter, compared to analyst estimates of $504.44 million. During the same period in the previous year, the firm earned $0.56 EPS. The firm's revenue was up 21.0% compared to the same quarter last year. As a group, equities research analysts anticipate that Enovis Co. will post 2.79 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on ENOV shares. JMP Securities assumed coverage on shares of Enovis in a report on Thursday, October 3rd. They issued an "outperform" rating and a $62.00 price objective on the stock. Evercore ISI lowered their price target on shares of Enovis from $62.00 to $58.00 and set an "outperform" rating on the stock in a research note on Tuesday, October 1st. Needham & Company LLC restated a "buy" rating and set a $65.00 price objective on shares of Enovis in a research note on Thursday, November 7th. Finally, JPMorgan Chase & Co. dropped their target price on Enovis from $53.00 to $50.00 and set a "neutral" rating on the stock in a report on Thursday, August 8th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $67.00.

Check Out Our Latest Stock Report on Enovis

Enovis Profile

(Free Report)

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.

See Also

Institutional Ownership by Quarter for Enovis (NYSE:ENOV)

→ AI breakthrough about to upend industry (From Porter & Company) (Ad)

Should you invest $1,000 in Enovis right now?

Before you consider Enovis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enovis wasn't on the list.

While Enovis currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Alphabet Gaining Momentum: Can It Reach $200 by December?

Alphabet Gaining Momentum: Can It Reach $200 by December?

Alphabet (GOOGL) is in the midst of a year-end rally, climbing 10% since September, and some analysts predict it could gain another 30% by Christmas!

Recent Videos

The Real Reason Tesla Stock Is Soaring – and Why Tech Expert Says It Won’t Stop
Best ETFs for 2025: Growth, Stability, and AI-Driven Investing
Broadcom Hits $1 Trillion – Can This AI Powerhouse Go Higher?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines